Jim Cramer's Mad Money Stock Recap Dec. 5
Risky Business: Boston Scientific (NYSE: BSX - News) and Johnson & Johnson (NYSE: JNJ - News)
Cramer says that the choice between BSX and JNJ is like a litmus test to determine how much risk an investor is willing to take. This Thursday, the FDA will decide whether controversial drug-coated stents will remain on the market. BSX and JNJ both make stents and have been hammered on news reports detailing health risks associated with the devices. Buying BSX on Wednesday would be "the higher risk, higher reward trade," while JNJ is more diversified and is less dependent on the FDA ruling, which will cause BSX to soar if it approves stents and will crush the stocks if stents are banned. "Buy it with money you are not afraid to lose and you can afford to lose," he said, and advised trading BSX as soon as it goes up. Cramer also suggested taking age into consideration when weighing risks, and would not invest in risky stocks after the age of 50, since younger investors can more easily recoup their losses. Cramer thinks that JNJ will go up on FDA approval of stents, but not as much as BSX will, although BSX has more downside, and ultimately a sense of one's own risk tolerance is essential when making decisions.
Cramer says that the choice between BSX and JNJ is like a litmus test to determine how much risk an investor is willing to take. This Thursday, the FDA will decide whether controversial drug-coated stents will remain on the market. BSX and JNJ both make stents and have been hammered on news reports detailing health risks associated with the devices. Buying BSX on Wednesday would be "the higher risk, higher reward trade," while JNJ is more diversified and is less dependent on the FDA ruling, which will cause BSX to soar if it approves stents and will crush the stocks if stents are banned. "Buy it with money you are not afraid to lose and you can afford to lose," he said, and advised trading BSX as soon as it goes up. Cramer also suggested taking age into consideration when weighing risks, and would not invest in risky stocks after the age of 50, since younger investors can more easily recoup their losses. Cramer thinks that JNJ will go up on FDA approval of stents, but not as much as BSX will, although BSX has more downside, and ultimately a sense of one's own risk tolerance is essential when making decisions.
Great Outdoors: Timberland (NYSE: TBL - News), VF. Corp (NYSE: VFC - News)
Cramer identifies TBL as an attractive takeover option for VFC, whose CEO Mackey McDonald did not rule out such an acquisition when he was interviewed by Cramer on last week's Mad Money. VFC has "tremendous bargaining power" and could get Timerberland into more stores. Even if the outdoor apparel maker fails to find a buyer, it has strong sales in Asia, a lot of cash and a good buyback program, although its fundamentals are a bit weak. "VF could do some great things here and I don't see any reason for it not to buy Timberland," Cramer said.
Mad Mail: Rite Aid (NYSE: RAD - News), Wal-Mart (NYSE: WMT - News), New York Stock Exchange (NYSE: NYX - News), Nymex (NYSE: NMX - News)
Responding to a letter, Cramer said that Rite Aid is his favorite speculative play and is rising because customers can walk to its stores, unlike Wal-Mart, which is located far away from residential areas. Cramer told another viewer that he prefers NYX to NMX, but would let the latter stock come down a bit before picking it up.
Cramer identifies TBL as an attractive takeover option for VFC, whose CEO Mackey McDonald did not rule out such an acquisition when he was interviewed by Cramer on last week's Mad Money. VFC has "tremendous bargaining power" and could get Timerberland into more stores. Even if the outdoor apparel maker fails to find a buyer, it has strong sales in Asia, a lot of cash and a good buyback program, although its fundamentals are a bit weak. "VF could do some great things here and I don't see any reason for it not to buy Timberland," Cramer said.
Mad Mail: Rite Aid (NYSE: RAD - News), Wal-Mart (NYSE: WMT - News), New York Stock Exchange (NYSE: NYX - News), Nymex (NYSE: NMX - News)
Responding to a letter, Cramer said that Rite Aid is his favorite speculative play and is rising because customers can walk to its stores, unlike Wal-Mart, which is located far away from residential areas. Cramer told another viewer that he prefers NYX to NMX, but would let the latter stock come down a bit before picking it up.
Labels: BSX, Jim Cramer, JNJ, Mad Money, NMX, NYX, RAD, TBL, VFC, WMT
posted by Stock Administrator @ 11:22 AM
0 Comments
